Eli Lilly poised for growth

Posted · Add Comment

After a rough five years, Lilly is rebounding, according to a May 31 article in the Indianapolis Star.

“By the end of this year, Lilly’s quarterly sales should return to growth mode and profits should be on the rebound. After falling 50 percent last year from 2013, to $3 billion, profit should jump to $3.4 billion this year, according to projections by Valuentum Securities investment research firm. It sees Lilly sales climbing back over the $20 billion mark this year, to $20.7 billion.”

New drugs and its growing animal health business, Elanco, are behind the optimistic outlook, as well as the company’s restructuring that included cutting $1 billion in spending and laying off 5,600 people.

Leave a Reply

Your email address will not be published. Required fields are marked *